文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

嗜酸性粒细胞增多综合征:心内科医生需关注的要点

Hypereosinophilic syndrome: considerations for the cardiologist.
PubMed 文献 · Heart · 2021-06-25

本文综述嗜酸性粒细胞增多综合征(HES)相关心脏损害的识别与管理。嗜酸性粒细胞介导的心内膜心肌损伤可致严重心肌病,心内科医生在早期诊断和治疗中起关键作用。早期无症状阶段血清肌钙蛋白和心脏MRI是最佳诊断工具,进展期可出现心内附壁血栓和心力衰竭,目前缺乏疾病特异性指南,相关心脏病变按经典国际推荐管理。

要点

  • HES患者早期可无症状,血清肌钙蛋白升高和心脏MRI有助于早期识别心肌受累。
  • 疾病进展可出现心内附壁血栓、瓣膜损害和心内膜下纤维化,超声心动图较易检出。
  • 心内膜心肌活检仅在困难情形考虑,需权衡风险获益,且可能因取样或纤维化替代而无贡献。

核心结论

  • 嗜酸性粒细胞介导的心内膜心肌损伤是HES的已知并发症,部分患者仍可因嗜酸性粒细胞增多控制不佳而发展为严重心肌病。
  • 心内科医生在HES相关心脏损害的早期检出和治疗中起关键作用。

研究设计与样本

  • 本文为综述,围绕HES患者嗜酸性粒细胞介导心脏损害的诊断与治疗进行论述。

主要发现

  • 早期一般无症状阶段与心内膜下嗜酸性粒细胞浸润相关,血清肌钙蛋白升高和心脏MRI是诊断的最佳工具。
  • 随疾病进展,患者典型出现心内附壁血栓,并可因瓣膜损害和/或心内膜下纤维化出现不同程度心力衰竭,这些更易通过传统超声心动图检查发现。
  • 应变成像和MRI特定序列等新影像手段有望检测细微异常并区分炎症期与纤维化期。

关键数值与推荐

  • 心内膜心肌活检可用于困难情形,即血嗜酸性粒细胞增多不明显时,但可能因取样问题、嗜酸性粒细胞脱颗粒或被纤维化替代而无贡献,且必须在仔细权衡风险获益后进行。
  • 目前没有针对嗜酸性粒细胞介导的血栓并发症和心脏病的共识性疾病的特异性指南,应按经典国际推荐管理。

临床怎么用

  • HES本身应由熟悉该罕见病的临床医生管理,目标是降低嗜酸性粒细胞计数以预防和治疗嗜酸性粒细胞介导的器官损害和功能障碍。
  • 心内科医生应参与管理HES相关心脏病,包括早期以血清肌钙蛋白和心脏MRI识别心肌受累。
  • 对进展期患者应关注心内附壁血栓、瓣膜损害和心力衰竭,并按经典国际推荐处理血栓并发症和心脏病。

局限性

  • 原文未报告具体研究样本量、数值阈值或统计学结果。
  • 心内膜心肌活检可能因取样问题、嗜酸性粒细胞脱颗粒或被纤维化替代而无贡献。
  • 缺乏针对嗜酸性粒细胞介导血栓并发症和心脏病的共识性疾病的特异性指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eosinophil-mediated endomyocardial damage is a well-known complication in patients with hypereosinophilic syndromes (HES). Although management and survival have improved significantly, some patients continue to develop severe cardiomyopathy as a direct consequence of uncontrolled hypereosinophilia. Cardiologists play a key role in early detection and treatment. At the early generally asymptomatic stage, related to subendocardial eosinophilic infiltrates, elevation of the biomarker of cardiac damage (serum troponin) and cardiac MRI are the best tools for diagnosis. As disease progresses, patients typically develop intracardiac mural thrombi and may experience variable degrees of heart failure due to valve damage and/or subendocardial fibrosis, all of which are more readily detectable with traditional echocardiographic investigation. New imaging modalities such as strain imaging and specific sequences in MRI offer the perspective of detecting subtle perturbations and distinguishing inflammatory versus fibrotic stages. Endomyocardial biopsy may help in difficult settings, namely, when blood eosinophilia is not prominent, but may be non-contributive due to sampling issues or eosinophil degranulation or replacement by fibrosis, and must always be performed after careful consideration of the risk:benefit ratio. Although treatment of the HES itself should be managed by clinicians with expertise in this rare disorder with the aim of lowering eosinophil counts to prevent and treat eosinophil-mediated organ damage and dysfunction, cardiologists play a key role in managing the associated cardiopathy. There are no consensual disease-specific guidelines for treating eosinophil-mediated thrombotic complications and cardiopathy, which should be managed according to classical international recommendations.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Bondue A, Carpentier C, Roufosse F, et al. Hypereosinophilic syndrome: considerations for the cardiologist. Heart. 2021. PMID: 34172539. doi:10.1136/heartjnl-2020-317202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。